There are important human and animal pathogens in the coronavirus family. In Wuhan, a city in the Hubei Province of China, a novel coronavirus was identified as the cause of a cluster of pneumonia cases with no known aetiology around the end of December 2019. The new coronavirus has quickly spread over the world, causing an epidemic in China, a pandemic, and a rising number of cases in many other nations. The 2019 coronavirus disease (COVID-19) is transmitted through the huge droplets coughed and sneezed by both symptomatic patients and asymptomatic people prior to the onset of their symptoms. The severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) incubation period is thought to last for 14 days after exposure, usually four to five days. All ages may become infected with SARS-CoV-2, but the majority do so in their middle years and beyond. Many COVID-19 patients experience long-lasting symptoms such as fatigue, shortness of breath, and neurological problems such as cognitive impairment months after the first infection. A large global health burden could result from this syndrome, also known as post-acute condition of SARS-CoV-2 infections (PASC) or post-COVID-19 condition, according to recent research. Fever, a dry cough, lethargy, headache, sore throat, rhinorrhea, conjunctivitis, nausea, vomiting, and diarrhoea are among the typical clinical symptoms. As a result, there are currently no distinctive clinical characteristics that reliably distinguish COVID-19 disease from other upper/lower airway viral infections. In a small percentage of instances, COVID-19 disease may progress to pneumonia, lung failure, and mortality by the end of the first week. Although there are more research looking at the post-COVID-19 condition, there is still no agreement on how this new disease should be defined, diagnosed, and treated in clinical practise, or how the outcomes should be evaluated. For both clinical and research objectives, there is an urgent need to enhance and standardise outcome indicators for this important patient group in order to facilitate data comparability and pooling. in order to harmonise, compare, and improve the quality of data across multiple geographic areas The purpose of this article is to examine the COVID-19 disease, starting with epidemiology and moving on to clinical signs, diagnosis, and its post-COVID consequences before coming to a conclusion and discussing potential therapy options. We advocate for an international effort that involves all significant players, including medical professionals, researchers, subject matter experts, patients, and carers. Keywords: COVID-19 Condition, Long COVID, Post-acute Condition of SARS-CoV-2 infection